Rare Disease Launch
A recent analysis in Health Affairs found that 65% of orphan drugs* are approved for only one orphan indication. Indeed, many of the companies that bring those drugs to market are often small biotechs with narrowly specialized disease expertise.
However, successfully bringing an orphan drug to market and reaching the patients who need it requires the same organizational structures and functions as multi-product pharmaceutical company.
Moreover, for a successful launch and marketing strategy, a thorough understanding of the market and its stakeholders as well as a broad set of expertise and operative capacity is needed.
For smaller biotechs, collaborating with experienced partners like The Healthonauts can be a good way to ensure success for a rare disease launch without having to build up all capacity in-house. The Healthonauts are an experienced team with long-standing expertise in the field of rare diseases, offering solutions that fit your needs, from strategy development to launch support and interim staffing of entire teams.
Get in touch if this sounds interesting!
* 491 drugs approved between 1990 and 2022